BioSpace News Archive

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the administration of EDIT-101, an experimental CRISPR gene editing medicine, to the first pediatric patient enrolled in the BRILLIANCE clinical trial, which is designed to test the safety of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2021 and fiscal year 2021.

Daewoong Pharmaceutical and HanAll Biopharma announced expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines.

Aviva Systems Biology, a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, announced the launch of its new service offering for high throughput Antibody Characterization Services.

Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an agreement with Merck, known as MSD outside the United States and Canada.

Melzi Surgical, a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced that it has closed its Series A financing for a total of over $4.0 million.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022.

OMNIVISION, a leading global developer of semiconductor solutions, including advanced digital imaging, analog and touch & display technology, today launched new laryngoscope reference designs that include a range of OMNIVISION products that help improve patient care by providing crisp, clear images for single-use video laryngoscopes.

Blue Water Vaccines Inc. a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced that Brian Price, Ph.D., Head of Technology Strategy, will deliver a presentation during the World Vaccine Congress 2022 in Washington, DC.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line treatment of extensive stage small cell lung cancer (ES-SCLC) has been accepted by the National Medical Products Administration (NMPA).